Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine.

Lai SW, Huang TC, Ye RH, Wu YY.

Eur J Haematol. 2015 Mar;94(3):273-6. doi: 10.1111/ejh.12365. Epub 2014 May 17.

PMID:
24797511
2.

Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome.

Tseng E, Alhusayen R, Sade S, Buckstein R, Prica A.

Br J Haematol. 2015 May;169(4):461. doi: 10.1111/bjh.13341. Epub 2015 Mar 12. No abstract available.

PMID:
25765235
3.

Necrotizing fasciitis in myelodysplastic syndrome: an exceptionally rare occurrence.

Niscola P, Tendas A, Cupelli L, Neri B, Scaramucci L, Morino L, Giovannini M, Fratoni S, de Fabritiis P.

Support Care Cancer. 2013 Feb;21(2):365-6. doi: 10.1007/s00520-012-1588-3. Epub 2012 Sep 8. No abstract available.

PMID:
22960853
4.

Safety and efficacy of azacitidine in myelodysplastic syndromes.

Vigil CE, Martin-Santos T, Garcia-Manero G.

Drug Des Devel Ther. 2010 Sep 24;4:221-9. Review.

5.

Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Voso MT, Breccia M, Lunghi M, Poloni A, Niscola P, Finelli C, Bari A, Musto P, Zambello R, Fianchi L, Alimena G, Leone G.

Eur J Haematol. 2013 Apr;90(4):345-8. doi: 10.1111/ejh.12079. Epub 2013 Feb 28.

PMID:
23336938
6.

Klebsiella pneumoniae necrotizing fasciitis in a Latin American male.

Persichino J, Tran R, Sutjita M, Kim D.

J Med Microbiol. 2012 Nov;61(Pt 11):1614-6. doi: 10.1099/jmm.0.043638-0. Epub 2012 Jul 19.

PMID:
22820688
7.

Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.

Almeida AM, Pierdomenico F.

Leuk Res. 2012 Sep;36(9):e211-3. doi: 10.1016/j.leukres.2012.04.029. Epub 2012 May 22. No abstract available.

PMID:
22622173
8.

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.

Ritchie EK.

Clin Interv Aging. 2012;7:165-73. doi: 10.2147/CIA.S24659. Epub 2012 Jun 19. Review.

9.

Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.

Xie M, Jiang Q, Xie Y.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):22-8. doi: 10.1016/j.clml.2014.04.010. Epub 2014 Jun 12. Review.

PMID:
25042977
10.

Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group.

Cseh AM, Niemeyer CM, Yoshimi A, Catala A, Frühwald MC, Hasle H, van den Heuvel-Eibrink MM, Lauten M, De Moerloose B, Smith OP, Bernig T, Gruhn B, Kulozik AE, Metzler M, Olcay L, Suttorp M, Furlan I, Strahm B, Flotho C.

Br J Haematol. 2016 Mar;172(6):930-6. doi: 10.1111/bjh.13915. Epub 2016 Jan 13.

PMID:
26766110
11.

Azacitidine-associated Sweet's syndrome.

Trickett HB, Cumpston A, Craig M.

Am J Health Syst Pharm. 2012 May 15;69(10):869-71. doi: 10.2146/ajhp110523.

PMID:
22555082
12.

Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.

Xicoy B, Jiménez MJ, García O, Bargay J, Martínez-Robles V, Brunet S, Arilla MJ, Pérez de Oteyza J, Andreu R, Casaño FJ, Cervero CJ, Bailén A, Díez M, González B, Vicente AI, Pedro C, Bernal T, Luño E, Cedena MT, Palomera L, Simiele A, Calvo JM, Marco V, Gómez E, Gómez M, Gallardo D, Muñoz J, de Paz R, Grau J, Ribera JM, Benlloch LE, Sanz G.

Leuk Lymphoma. 2014 Jun;55(6):1300-3. doi: 10.3109/10428194.2013.834532. Epub 2013 Sep 16.

PMID:
23952246
13.

Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.

Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert M.

Blood. 2007 Aug 1;110(3):1080-2; author reply 1083. No abstract available.

14.

Decitabine dosage in myelodysplastic syndromes.

Giagounidis AA.

Blood. 2007 Aug 1;110(3):1082-3; author reply 1083. No abstract available.

15.

[Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes].

Dvirnyk VN, Kokhno AV, Glasko EN, Gemdzhian ÉG, Diagileva OA, Platonova TL, Parovichnikova EN.

Ter Arkh. 2013;85(7):65-71. Russian.

PMID:
24137949
16.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; Cancer and Leukemia Group B..

J Clin Oncol. 2006 Aug 20;24(24):3895-903.

PMID:
16921040
17.

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.

Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM)..

Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7.

PMID:
25449687
18.

Acute myeloblastic leukemia.

Molina CA, Rodríguez MJ, de Marcos NS, Font P.

Adv Ther. 2011 Mar;28 Suppl 3:10-6. doi: 10.1007/s12325-010-0109-3. Epub 2011 Mar 9.

PMID:
21431629
19.

Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry.

Grinblatt DL, Sekeres MA, Komrokji RS, Swern AS, Sullivan KA, Narang M.

Leuk Lymphoma. 2015 Apr;56(4):887-95. doi: 10.3109/10428194.2014.935366. Epub 2014 Aug 20.

PMID:
24956145
20.

Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan.

Hayashi M, Takayasu H, Tada M, Yamazaki Y, Tateno H, Tazawa S, Wakabayashi A, Iwasaki T, Tsuchiya Y, Yamashita J, Takeda N, Tomita S, Mori H, Kokubu F.

Intern Med. 2012;51(17):2411-5. Epub 2012 Sep 1. Review.

Supplemental Content

Support Center